爱尚大众

Wuhan Dazhong Dental Medical Co., Ltd.

武漢大眾口腔醫療股份有限公司

(A joint stock company with limited liability incorporated in the People's Republic of China)

(Stock Code: 2651)

PROPOSED CHANGE OF EXECUTIVE DIRECTOR

The board (the "**Board**") of directors (the "**Director(s)**") of Wuhan Dazhong Dental Medical Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") received the resignation letter from Mr. Guo Jiaping ("**Mr. Guo**"), an executive Director and a vice general manager of the Company. Mr. Guo has resigned as the executive Director of the fourth session of the Board and a vice general manager of the Company to devote more time to his personal endeavours. Mr. Guo's resignation shall take effect on the commencement date of the term of office of Mr. Wang Hong ("**Mr. Wang**")'s appointment as the executive Director.

Mr. Guo has confirmed that he has no disagreement with the Board and there are no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company (the "**Shareholders**") and/or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

The Board is pleased to announce that the Board has proposed to elect and appoint Mr. Wang as the executive Director of the fourth session of the Board. The appointment of Mr. Wang as the executive Director shall be subject to the approval of the Shareholders at the extraordinary general meeting of the Company to be held at No. 8 Conference Room, 11/F, Huayin Building, No. 786 Minzhu Road, Zhongnan Road Sub-District, Wuchang District, Wuhan, Hubei Province, PRC at 9:00 a.m. on Monday, September 21, 2026 (the "**EGM**").

The biographical details of Mr. Wang are as follows:

Mr. Wang, aged 63, joined our Group in January 2021 as a vice general manager of our Company. He is primarily responsible for the daily operation of our medical institutions outside Wuhan, PRC. Mr. Wang also served as directors of various subsidiaries of the Company.

Mr. Wang has over 30 years of experience in medical and healthcare industry. Prior to joining the Group, he served as the sales effective manager and head of global dermatology division in Xi'an Janssen Pharmaceutical Co., Ltd. (西安楊森製藥有限公司) from May 1994 to December 2002, primarily responsible for its marketing and business development. He then successively served as the nationwide marketing director, deputy general manager of marketing and the vice president in Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (正大天晴藥業集團股份有限公司), a subsidiary of Sino Biopharmaceutical Limited (Stock code: 1177.HK), from December 2002 to December 2020, where he was responsible for its nationwide marketing and sales.

Mr. Wang obtained his associate diploma in animal husbandry from Henan University of Animal Husbandry and Economy (河南牧業經濟學院) in July 1984 and his master's degree in pathology from Shanghai Medical University (上海醫科大學) in July 1991. He also obtained an executive master of business administration degree from the National University of Singapore in August 2002.

Mr. Wang will enter into a service contract with the Company to serve as an executive Director for a term commencing on the date of approval by the Shareholders of his appointment at the EGM and ending on the earlier of (i) the third annual general meeting of the Company held after the date of his appointment, (ii) the expiry of the term of the current session of the Board, or (iii) the completion of three years from the date of his appointment. Mr. Wang will not receive any remuneration, including director fee, salary, bonus and allowance for his appointment as an executive Director. As the vice general manager of the Company, he is entitled to an annual salary of RMB480,000.

As at the date of this announcement, Mr. Wang holds 103,000 unlisted shares of the Company ("**Unlisted Shares**"), representing 0.32% of the total number of the issued Unlisted Shares and 0.20% of the total number of the issued shares of the Company and 10,000 H shares of the Company ("**H Shares**"), representing 0.05% of the total number of the issued H Shares and 0.02% of the total number of the issued shares of the Company. In addition, Mr. Wang holds 3,000,000 shares in Hubei Zhongshan Medical Investment Management Co., Ltd. ("**Zhongshan Medical Investment**"), representing approximately 2.58% of the equity interest in Zhongshan Medical Investment. As at the date of this announcement, Zhongshan Medical Investment holds 31,324,102 Unlisted Shares, representing 96.82% of the total number of the issued Unlisted Shares and 61.93% of the total number of the issued shares of the Company.

Save as disclosed above, as at the date of this announcement, Mr. Wang (i) does not have any other interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) has not held any other positions with the Company or other members of the Group; (iii) has not been a director of any public company, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years and other major appointments and professional qualifications; (iv) does not have any relationship with any Director, senior management or substantial or controlling Shareholders; (v) has no other information that needs to be disclosed pursuant to paragraphs (h) to (v) of Rule 13.51(2) of the Listing Rules; and (vi) has no other matter that needs to be brought to the attention of the Shareholders.

EGM

The resolution in relation to the proposed appointment of Mr. Wang as the executive Director was considered and approved by the Board on September 4, 2026, and is now proposed to the Shareholders at the EGM for consideration and approval by way of an ordinary resolution.

A supplemental circular and supplemental notice containing, among other things, the proposed appointment of Mr. Wang as the executive Director, biographical details and other relevant information of Mr. Wang and a supplemental notice of the EGM will be dispatched to the Shareholders as soon as practicable.

By order of the Board
Wuhan Dazhong Dental Medical Co., Ltd.
Mr. Yao Xue
Chairman and Executive Director

Wuhan, Hubei Province, PRC
September 4, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Yao Xue, Ms. Shen Hongmin, Mr. Guo Jiaping and Ms. Liu Hongchan as executive Directors; and (ii) Mr. Shu Yijie, Ms. Huang Suzhen and Mr. Xie Dong as independent non-executive Directors.